GLP-1 Education · 038
SELECT in Practice: Discussing Cardiovascular Evidence with Precision
Translate a cardiovascular outcomes trial into a careful patient conversation and a documented clinical decision.
Dr. Sherry-Ann Brown, MD, PhD, FACC, FAHA
Describe the studied population
SELECT enrolled adults aged at least 45 years with established cardiovascular disease, BMI at least 27, and no diabetes history. Semaglutide reduced the primary cardiovascular composite relative to placebo. These brief trial findings provide an evidence anchor; the practice framework below is original synthesis.
Check the clinical match
Review the patient's documented cardiovascular history, weight related diagnosis, diabetes status, other conditions, and current treatment. Identify which features align with the trial and which require broader clinical interpretation. Then verify the exact product's present indication and safety information before prescribing. Ask what the patient hopes to gain from treatment and what concerns may affect their decision. This separates the process of understanding a trial from the individual decision of choosing a medicine within a complete prevention plan.
Explain the result usefully
Describe the outcome being discussed and the period over which the trial observed it. If presenting numerical benefit, provide the original event rates and timeframe alongside the relative estimate. Explain that population results inform expectations and that an individual's outcome remains uncertain. Invite the patient to tell you how the information affects their preferences. Continue addressing established cardiovascular care, medication use, smoking where relevant, nutrition, and feasible activity. The trial becomes one component of a conversation about the patient's overall risk and treatment priorities.
Document the decision and its followup
Record the relevant cardiovascular diagnosis, evidence considered, product selected, safety review, and the patient's priorities. Include practical access concerns and the agreed monitoring plan. At followup, assess tolerability, adherence, and the broader prevention plan. Review whether the treatment remains feasible and whether new clinical information changes the decision. A clear note helps primary care and cardiology work from the same understanding and allows a future clinician to see why this particular therapy was considered for this particular patient.
Put the headline into absolute context
In SELECT, the primary event occurred in 6.5% of semaglutide participants and 8.0% of placebo participants over a mean 39.8 months. Presenting these observed proportions beside the relative estimate gives patients a concrete scale. Discuss how their own clinical context affects applicability and explain that these trial proportions describe groups followed within a defined research setting.
Apply the framework
A patient with a prior myocardial infarction asks whether an obesity medicine could also affect cardiovascular risk. Review the documented history, establish the clinical match to SELECT, and verify current labeling. Explain the studied outcome in plain language, assess the patient's preferences, and create an ongoing plan that connects medication monitoring with the rest of their cardiovascular care.